345 related articles for article (PubMed ID: 25712659)
1. The cyclic AMP effects and neuroprotective activities of PACAP and VIP in cultured astrocytes and neurons exposed to oxygen-glucose deprivation.
Jóźwiak-Bębenista M; Kowalczyk E; Nowak JZ
Pharmacol Rep; 2015 Apr; 67(2):332-8. PubMed ID: 25712659
[TBL] [Abstract][Full Text] [Related]
2. Effects of PACAP, VIP and related peptides on cyclic AMP formation in rat neuronal and astrocyte cultures and cerebral cortical slices.
Jozwiak-Bebenista M; Dejda A; Nowak JZ
Pharmacol Rep; 2007; 59(4):414-20. PubMed ID: 17901570
[TBL] [Abstract][Full Text] [Related]
3. Effects of PACAP and VIP on cyclic AMP formation in rat neuronal and astrocyte cultures under normoxic and hypoxic condition.
Nowak JZ; Jozwiak-Bebenista M; Bednarek K
Peptides; 2007 Sep; 28(9):1706-12. PubMed ID: 17521773
[TBL] [Abstract][Full Text] [Related]
4. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI.
Dejda A; Sokołowska P; Nowak JZ
Pharmacol Rep; 2005; 57(3):307-20. PubMed ID: 15985713
[TBL] [Abstract][Full Text] [Related]
6. Effects of PEDF and VEGF on PACAP-/VIP-induced cAMP formation in rat brain derived astrocyte cultures.
Klaska I; Bednarek K; Nowak JZ
Pharmacol Rep; 2008; 60(6):1019-24. PubMed ID: 19211999
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide.
Aoki Y; Iwasaki Y; Katahira M; Oiso Y; Saito H
Endocrinology; 1997 May; 138(5):1930-4. PubMed ID: 9112389
[TBL] [Abstract][Full Text] [Related]
9. Effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on cyclic AMP accumulation in sheep pituitary cells in vitro.
Sawangjaroen K; Sernia C; Curlewis JD
J Endocrinol; 1996 Mar; 148(3):545-52. PubMed ID: 8778233
[TBL] [Abstract][Full Text] [Related]
10. PACAP, VIP, and PHI: effects on AC-, PLC-, and PLD-driven signaling systems in the primary glial cell cultures.
Dejda A; Jozwiak-Bebenista M; Nowak JZ
Ann N Y Acad Sci; 2006 Jul; 1070():220-5. PubMed ID: 16888170
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.
Brenneman DE
Peptides; 2007 Sep; 28(9):1720-6. PubMed ID: 17513014
[TBL] [Abstract][Full Text] [Related]
12. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
13. Effects of PACAP and VIP on cAMP-generating system and proliferation of C6 glioma cells.
Sokolowska P; Nowak JZ
J Mol Neurosci; 2008 Nov; 36(1-3):286-91. PubMed ID: 18491045
[TBL] [Abstract][Full Text] [Related]
14. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs.
Rawlings SR; Piuz I; Schlegel W; Bockaert J; Journot L
Endocrinology; 1995 May; 136(5):2088-98. PubMed ID: 7720658
[TBL] [Abstract][Full Text] [Related]
16. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage.
Stumm R; Kolodziej A; Prinz V; Endres M; Wu DF; Höllt V
J Neurochem; 2007 Nov; 103(4):1666-81. PubMed ID: 17868305
[TBL] [Abstract][Full Text] [Related]
18. Regulation of growth hormone release in common carp pituitary cells by pituitary adenylate cyclase-activating polypeptide: signal transduction involves cAMP- and calcium-dependent mechanisms.
Xiao D; Chu MM; Lee EK; Lin HR; Wong AO
Neuroendocrinology; 2002 Nov; 76(5):325-38. PubMed ID: 12457043
[TBL] [Abstract][Full Text] [Related]
19. Cyclic AMP formation in C6 glioma cells: effect of PACAP and VIP in early and late passages.
Sokolowska P; Nowak JZ
Ann N Y Acad Sci; 2006 Jul; 1070():566-9. PubMed ID: 16888226
[TBL] [Abstract][Full Text] [Related]
20. PACAP-38 induces neuronal differentiation of human SH-SY5Y neuroblastoma cells via cAMP-mediated activation of ERK and p38 MAP kinases.
Monaghan TK; Mackenzie CJ; Plevin R; Lutz EM
J Neurochem; 2008 Jan; 104(1):74-88. PubMed ID: 17995938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
